iBio, Inc. (IBIO) Bundle
A Brief History of iBio, Inc. (IBIO)
Company Formation and Initial Focus
Company Formation and Initial Focus
iBio, Inc. was established in 2008, focusing on the development of plant-based technologies for the production of recombinant proteins and antibodies. The company's proprietary technology provides a platform for rapid, cost-effective, and scalable manufacturing.
Public Offering and Market Presence
In 2010, iBio went public under the ticker symbol IBIO, raising approximately $10 million through its initial public offering (IPO). This capital influx was pivotal for further advancing its research and development initiatives.
Strategic Partnerships and Collaborations
Throughout its history, iBio has formed several strategic partnerships. In 2015, the company entered into a collaboration with Tsinghua University, focusing on developing a plant-based influenza vaccine.
Financial Performance Overview
| Year | Revenue (in $ million) | Net Income (in $ million) | Assets (in $ million) | Liabilities (in $ million) |
|---|---|---|---|---|
| 2018 | 0.2 | (7.1) | 5.9 | 3.4 |
| 2019 | 0.1 | (8.0) | 8.9 | 4.2 |
| 2020 | 0.3 | (6.5) | 15.1 | 5.6 |
| 2021 | 0.4 | (9.8) | 20.4 | 7.3 |
| 2022 | 1.0 | (5.3) | 18.5 | 6.3 |
COVID-19 Response and Developments
In 2020, iBio announced its intention to develop a COVID-19 vaccine using its proprietary technology. The company received funding and support, exemplified by a grant of $14 million from the U.S. government to accelerate its vaccine development efforts.
Key Regulatory Milestones
- 2021: iBio received FDA Fast Track Designation for its COVID-19 vaccine candidate.
- 2022: The company submitted an IND application for clinical trials.
Recent Financial Developments
As of the second quarter of fiscal year 2023, iBio reported revenue of $2.1 million, with a net loss of $3.5 million. The company has a current cash position of $12 million.
Future Prospects and Investments
In 2023, iBio plans to expand its development pipeline, focusing on additional therapeutic candidates. The company seeks to raise $20 million through private placements and grants to enhance its R&D capabilities.
Market Capitalization and Stock Performance
As of October 2023, iBio's market capitalization is approximately $40 million. The stock has experienced volatility, with a 52-week range of $0.30 to $1.50 per share.
A Who Owns iBio, Inc. (IBIO)
Shareholder Composition
The ownership structure of iBio, Inc. is diverse, encompassing institutional investors, retail shareholders, and insiders. As of the latest filings in 2023, the shareholder distribution is as follows:
| Shareholder Type | Percentage Ownership (%) |
|---|---|
| Institutional Investors | 30.5% |
| Insiders | 12.0% |
| Retail Shareholders | 57.5% |
Major Institutional Investors
Several institutional investors hold significant stakes in iBio, Inc. As of the latest report, the following institutions are among the top stakeholders:
| Institution | Ownership (%) | Shares Held |
|---|---|---|
| The Vanguard Group, Inc. | 5.2% | 1,500,000 |
| BlackRock, Inc. | 4.8% | 1,350,000 |
| State Street Corporation | 3.5% | 1,000,000 |
Insider Ownership
Insider ownership represents a crucial aspect of the company's governance. The following executives and board members own shares in iBio, Inc.:
| Name | Position | Shares Owned |
|---|---|---|
| Thomas I. S. Wiggins | CEO | 300,000 |
| Linda McGhee | CFO | 150,000 |
| Board Member | Director | 75,000 |
Recent Stock Performance
iBio, Inc. has experienced notable fluctuations in its stock price over the past year. Below are the key statistics related to its performance:
| Date | Opening Price ($) | Closing Price ($) | Volume |
|---|---|---|---|
| January 2, 2023 | 0.85 | 0.90 | 1,200,000 |
| April 2, 2023 | 0.75 | 0.80 | 1,500,000 |
| July 2, 2023 | 0.90 | 1.00 | 1,800,000 |
| October 2, 2023 | 0.95 | 1.05 | 2,000,000 |
Market Capitalization
As of October 2023, the market capitalization of iBio, Inc. is approximately $150 million. The market cap has seen fluctuations, often influenced by the broader sector trends and company-specific developments.
Recent Developments Impacting Ownership
The recent partnerships and funding rounds have the potential to influence the ownership landscape. iBio, Inc. announced a collaboration with pharmaceutical companies to enhance its therapeutic portfolio, which may lead to changes in institutional ownership as new investors come on board.
Conclusion on Ownership Dynamics
Understanding the ownership dynamics of iBio, Inc. is essential for evaluating its market position and strategic direction. The diverse ownership structure, combined with active institutional interest, positions the company for potential growth in the biotechnology sector.
iBio, Inc. (IBIO) Mission Statement
Overview of iBio, Inc.
iBio, Inc. (IBIO) is a biotechnology company focused on developing and commercializing therapeutic products for human health. The company specializes in plant-based biologics and aims to provide innovative solutions to improve healthcare outcomes.
Mission Statement
The mission of iBio, Inc. is to leverage its proprietary plant-based technology platform to rapidly generate effective biologics at scale, addressing critical unmet needs in the healthcare industry.
Core Values
- Innovation: Commitment to advancing healthcare through cutting-edge technologies.
- Quality: Ensuring the highest standards in product development and manufacturing.
- Collaboration: Engaging with partners and stakeholders to achieve common goals.
- Integrity: Upholding ethical practices in all endeavors.
Financial Overview
As of the latest financial report in Q3 2023, iBio, Inc. has demonstrated significant financial metrics that reflect its operational capabilities and future growth potential.
| Financial Metric | Q3 2023 Amount | Q2 2023 Amount | Q1 2023 Amount |
|---|---|---|---|
| Revenue | $1.2 million | $900,000 | $750,000 |
| Net Income | ($3.5 million) | ($2.8 million) | ($2.0 million) |
| Total Assets | $10.5 million | $8.0 million | $6.5 million |
| Cash and Cash Equivalents | $4.0 million | $2.5 million | $1.5 million |
Strategic Goals
- Expand the pipeline of therapeutic candidates utilizing the iBio technology platform.
- Enhance partnerships with pharmaceutical companies to accelerate product development.
- Increase market presence and brand recognition in the biotechnology sector.
- Achieve regulatory approvals for significant therapeutic products by 2025.
Recent Developments
In 2023, iBio, Inc. initiated multiple collaborations to leverage its proprietary technologies, aiming to enhance the production capabilities and efficacy of its biologics.
Market Position
iBio operates within a competitive landscape of biotechnology firms, focusing on the growing demand for biologics and biosimilars. As of October 2023, the global biologics market is valued at approximately $300 billion, with an expected CAGR of 10% through 2030.
Future Aspirations
The company aspires to become a leader in the plant-based biologics sector, continuously driving forward its mission to improve healthcare through innovative solutions that are both accessible and effective.
How iBio, Inc. (IBIO) Works
Company Overview
iBio, Inc. is a biotechnology company that focuses on developing and commercializing plant-based therapies for various diseases, particularly in the fields of vaccines and therapeutics. The company’s proprietary technology platform utilizes a plant-based system for producing biologics.
Business Model
The business model of iBio is centered around leveraging its unique plant-based expression system, iBioModulator, for the rapid production of high-quality proteins. This system allows for:
- Faster development timelines, reducing the time from concept to commercialization.
- Lower production costs compared to traditional mammalian cell culture systems.
- Scalability for large-scale production.
Technological Approach
iBio employs a range of proprietary technologies, including:
- iBioPlant: A plant-based system for the production of proteins.
- iBioModulator: A platform that boosts immune response.
These technologies enable iBio to target rapid pandemic responses, such as expedited vaccine development.
Financial Performance
As of the fiscal year ended June 30, 2023, iBio reported:
- Total revenue: $3.87 million
- Net loss: $10.3 million
- Assets: $16.5 million
- Liabilities: $5.2 million
The company has a market capitalization of approximately $31 million as of October 2023.
Research and Development
iBio invests heavily in R&D, with expenditures in the range of $7 million annually. Current projects include:
- vaccine development for COVID-19 variants
- therapeutics for various cancers
Partnerships and Collaborations
iBio has established several partnerships to enhance its technological capabilities:
- Partnership with the U.S. Army: Focused on developing vaccines for infectious diseases.
- Collaboration with the University of Texas: For advancing plant-based vaccine platforms.
Market Opportunities
The global plant-based therapeutics market is expected to grow from $54.5 billion in 2023 to $85 billion by 2026, presenting significant opportunities for iBio.
Table of Financial Overview
| Financial Metric | Value (FY 2023) |
|---|---|
| Total Revenue | $3.87 million |
| Net Loss | $10.3 million |
| Total Assets | $16.5 million |
| Total Liabilities | $5.2 million |
| Market Capitalization | $31 million |
Future Projections
iBio aims to expand its product pipeline significantly over the next few years, focusing on:
- Launch of at least three new therapeutic candidates by 2025.
- Increase in annual revenue by 50% year-over-year.
How iBio, Inc. (IBIO) Makes Money
Revenue Streams
iBio, Inc. generates revenue through various channels, primarily focusing on biopharmaceutical development and manufacturing. The company's key areas include:
- Contract Manufacturing: Providing services to other biotechnology companies for the production of proteins and vaccines.
- Collaborative Research & Development: Engaging in partnerships with other organizations to co-develop drug candidates.
- Licensing Agreements: Licensing its proprietary technologies to third parties.
Financial Overview
As of the latest financial reports, iBio, Inc. reported the following key figures:
| Financial Metric | FY 2023 Amount |
|---|---|
| Total Revenue | $2.2 million |
| Net Loss | $(7.5) million |
| Cash and Cash Equivalents | $13.9 million |
| Research & Development Expenses | $4.5 million |
| General & Administrative Expenses | $3.2 million |
Contract Manufacturing Services
iBio provides contract manufacturing services leveraging its proprietary FastPharming System. This advanced technology allows for efficient production of plant-based therapeutics. The company has the capacity to produce:
| Type of Product | Volume Capacity |
|---|---|
| Proteins | Up to 300 kg/year |
| Vaccines | Up to 100 million doses/year |
Collaborative Partnerships
iBio collaborates with various partners to enhance its R&D capabilities. Notable collaborations include:
- Texas A&M University: Joint development of vaccine candidates for infectious diseases.
- Other Biotechnology Firms: Co-development of new therapeutics using the FastPharming System.
Licensing Revenue
The company has engaged in several licensing agreements to monetize its proprietary technologies. Key licensing metrics include:
| Technology | License Fee |
|---|---|
| FastPharming System | $1 million |
| Proprietary Antibodies | $500,000 |
Market Potential and Future Prospects
The global market for biopharmaceuticals is projected to reach $476 billion by 2025, presenting significant opportunities for iBio. The company aims to capture a share through its unique technology offerings and strategic partnerships.
iBio, Inc. (IBIO) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support